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Objective/background: Tuberculosis (TB) remains the leading cause of AIDS-related deaths
among adults in countries with resource limitations. The emergence of the Xpert MTB/
RIF rapid molecular assay and its subsequent World Health Organization endorsement in
2010 transformed the TB-diagnostic landscape. Xpert provided diagnostic accuracy that
was far superior to that of the sputum-smear microscopy test previously used. The detec-
tion of mycobacterial lipoarabinomannan (LAM) antigen in urine has emerged as a poten-
tial point-of-care test for TB. LAM antigen is a lipopolysaccharide present in mycobacterial
cell walls which is released from metabolically active or degenerating bacterial cells and
appears to be present only in people with active TB. Urine-based testing has advantages
over sputum-based testing because urine is easy to collect and store and lacks the infection
control risks associated with sputum collection. A previously study reported that urinary-
LAM testing is a rapid, low-cost, ante-mortem diagnosis for human immunodeficiency
virus (HIV)-associated TB. The objective of this study was to investigate the levels of LAM
in HIV patients referred to the Mashih Daneshvari Hospital Tehran, Iran.
Methods: Urine from 31 HIV patients without TB, 33 HIV patients with pulmonary TB, and
eight HIV patients with extrapulmonary TB was analyzed for LAM using enzyme-linked
immunosorbent assay kits (Mybiosource, San Diego, CA, USA).
Results: The plasma levels of LAM in pulmonary TB/HIV patients was 7.67 ± 2.3 ng/ml com-
pared with 4.5 ± 1.6 ng/ml in extrapulmonary TB/HIV and 6.7 ± 1.2 ng/ml in HIV patientsulosis and
ts with or
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without coinfection with Tuberculosis in Iran.without TB. Therewasno significant difference inurine LAMlevelsbetween the threegroups.
Conclusion: Our results highlight the limitations of using urine LAM levels for differentiating
HIV-associated TB patients in Iran.Conflicts of interest
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